As an organisation committed to the responsible and safe use of CBD products, we understand the importance of evidence-based recommendations to protect public health.
Our scientific panel will examine the scientific evidence to better understand how the FSA has come to its conclusion. We will make further comments once our experts have completed their review.
We urge retailers to take this as guidance, which it is. Nothing will change immediately in terms of products included on the FSA’s public list.
We highlight to consumers that this guidance demonstrates the FSA still considers CBD to be safe and their advice relates to lifetime consumption of daily high doses of CBD.
In light of this updated advice, the ACI trusts that the FSA, after considering the implications of their announcement, will find a suitable solution for companies that have invested heavily to submit Novel Foods authorisation applications for their products.
We remain committed to engage with the FSA to support our members who have acted in good faith throughout the Novel Foods process so far.
